ResMed Inc. (RMD)
NYSE: RMD · Real-Time Price · USD
228.42
+0.17 (0.07%)
Sep 17, 2026, 4:00 PM EDT - Market closed
ResMed Stock Forecast
Stock Price Forecast
According to 19 analysts polled by S&P Global, ResMed stock has a consensus rating of "Buy" and an average price target of $246.44. The average 1-year stock price forecast is 7.89% higher than the current stock price, while the lowest is $175 (-23.39%) and the highest is $320 (+40.09%).
Price Target: $246.44 (+7.89%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for ResMed stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 8 | 8 | 6 | 6 | 6 |
| Buy | 3 | 2 | 1 | 1 | 1 | 1 |
| Hold | 7 | 7 | 8 | 10 | 11 | 11 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 18 | 18 | 18 | 18 | 19 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Upgrades $244 → $262 | Buy | Upgrades | $244 → $262 | +14.70% | Sep 15, 2026 |
| Citi | Citi | Hold Maintains $235 → $240 | Hold | Maintains | $235 → $240 | +5.07% | Sep 10, 2026 |
| KeyBanc | KeyBanc | Buy Reiterates $255 → $267 | Buy | Reiterates | $255 → $267 | +16.89% | Aug 31, 2026 |
| Rothschild & Co Redburn No rating | Rothschild & Co Redburn | Hold Initiates $230 | Hold | Initiates | $230 | +0.69% | Aug 19, 2026 |
| Mizuho Securities | Mizuho Securities | Buy Maintains $220 → $235 | Buy | Maintains | $220 → $235 | +2.88% | Aug 12, 2026 |
Financial Forecast
Revenue This Year
5.81B
from 5.65B
Increased by 2.79%
Revenue Next Year
6.19B
from 5.81B
Increased by 6.52%
EPS This Year
12.08
from 11.17
Increased by 8.14%
EPS Next Year
13.22
from 12.08
Increased by 9.48%
EPS and Forward PE are based on non-GAAP adjusted numbers.